Author

Leigh A. Bradley

University of Virginia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Jeffrey J. SaucermaniD· 2 shared Matthew J. WolfiD· 2 shared Alexander J Eichert· 1 shared Alexander Young· 1 shared Bryana N. Harris· 1 shared Bryce Cameron MurilloiD· 1 shared Caitlin M. PaveleciD· 1 shared Catherine Zhao· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Jeffrey J. SaucermanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Network Modeling Predicts How DYRK1A Inhibition Promotes Cardiomyocyte Cycling after Ischemic/Reperfusion Injury

Bryce Cameron Murillo, Alexander Young, Kaitlyn L. Wintruba, Alexander J Eichert, Klara Siejda, Dennon Hoernig, Leigh A. Bradley, Bryana N. Harris, Catherine Zhao, MIchelle Wu, Emmanuel Deau, Mattias F. Lindberg, Laurent Meijer, Jeffrey J. Saucerman, Matthew J. Wolf

The paper develops a computational network model predicting DYRK1A inhibition promotes cardiomyocyte cycling after ischemic/reperfusion injury, validated through experiments in neonatal rat cardiomyocytes.

JCI Insight · Sep 17, 2026Peer-reviewedPharmacology & Toxicology

Therapeutic targeting of MYBPC3 mutation-specific hypertrophic cardiomyopathy guided by network modeling

Pichayathida Luanpaisanon, Caitlin M. Pavelec, Leigh A. Bradley, Jeffrey J. Saucerman, Matthew J. Wolf

This study identifies mTOR as a therapeutic target for MYBPC3 mutation-induced hypertrophic cardiomyopathy using network modeling and experimental validation.

bioRxiv · Sep 8, 2026 · PreprintPhysiology